PhD, University at Buffalo School of Pharmacy and Pharmaceutical Sciences (2010)
MS, National Institute of Pharmaceutical Education and Reserach (2003)
BPharm, Gujarat University (2002)
Employment:
Principle Scientist, Translational Research, PK/PD Modeling and Simulation, Pfizer Inc. (2013)
Senior Scientist, Translational Research, PK/PD Modeling and Simulation, Pfizer Inc. (2010–2013)
Awards and Honors:
UB Exceptional Scholar: 2016 Young Investigator Award (2016)
Outstanding Manuscript in Modeling and Simulation Award - 2014 AAPS annual meeting (2014)
Individual Performance Awards (2013)
2010 AAPS Graduate Student Symposium Award in PPDM and CPTR (2010)
Who’s Who Among Students in American Universities and Colleges (2009)
Graduate Scholar Award (2009)
AAPS Outstanding Manuscript in Modeling and Simulation Award (2009)
First Prize outstanding podium presentation (2009)
Best poster and presentation award (2009)
Cover page of Journal of PKPD
Grants and Sponsored Research:
May 2015–March 2020 Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics NIGMS-NIH Role: Principal Investigator $1,500,000
July 2018–December 2019 University at Buffalo School of Pharmacy and Pharmaceutical Sciences Seed Grant Program University at Buffalo School of Pharmacy and Pharmaceutical Sciences Role: Co-Investigator $10,000
August 2017–July 2018 Center for Protein Therapeutics UBSPPS Role: Principal Investigator $100,000
August 2017–July 2018 Center for Protein Therapeutics UBSPPS Role: Principal Investigator $100,000
July 2017–June 2018 Oncolinx Post-Doctoral Fellowship UBSPPS Role: Principal Investigator $87,150
August 2016–July 2017 Center for Protein Therapeutics Role: Principal Investigator $100,000
August 2015–July 2016 Center for Protein Therapeutics UBSPPS Role: Principal Investigator $100,000
July 2014–June 2016 Roche Pharmaceutical Post-Doctoral Fellowship UBSPPS Role: Principal Investigator $272,840
PK/PD of Novel Biological Construct; Advisory board member (2013–present)
Bioanalytical Method & Modeling Integration Summit; Advisory board member (2013–present)
The 3rd Pharmacokinetics & Pharmacodynamics; Advisory board member (2012–present)
Global PK/PD Network at Pfizer Inc; • Chair (2011–present)
The Dean’s Student Ambassador (2008–2010)
UB-Pharmaceutics Graduate Student Association; President & Vice President (2007–2008)
American Association of Pharmaceutical Scientists; Member (2004–present)
Presentations:
"Development of Translational PK Model for Characterizing and Predicting Protein Therapeutics Disposition in Brain" The National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous System Disorders. (2017)
"Quantitative Characterization of the Bystander Effect of ADCs." 7th World ADC Summit (2017)
"Bench-to-bedside translation of ADCs using PKPD M&S" World Conference on Pharmacometrics (WCOP) (2016)
"Model-based Drug Development of Protein Therapeutics" 11th International International Society for the Study of Xenobiotics (ISSX) Meeting (2016)
"Platform PBPK Model for Biologics and Its Evolution Towards Pediatric Population" Gordon Research Conference on Drug Metabolism (2015)
"Model Based Development of Antibody Drug Conjugates" Clinical & Pharmaceutical Solutions through Analysis Conference 2014 (2014)
"Quantitative PKPD Approaches to Guide the Discovery and Development of ADCs" , Green Cross Pharmaceuticals (2014)
"Preclinical to Clinical Translation of Antibody Drug Conjugate (ADC) Efficacy using PK/PD Modeling and Simulation" 2013 AAPS Webinar Series, CPTR (2013)
"Development and Validation of a Mechanism Based PK/PD Model for Preclinical to Clinical Translation of ADC Efficacy" PK/PD of Antibody-Derived Molecules: Improving Pre-Clinical Results for Clinical Success, PEGS Inaugural (2013)
"Development and Validation of the multi-scaled mechanistic PK/PD model for ADCs" PK/PD of Novel Constructs Conference, Cambridge Healthtech Institute (2013)
"Employing PK/PD modeling and simulation to guide ADC development" 2013 World ADC Summit (2013)
"Evolving PBPK Modeling to Predict the PK and Appropriate Doses of Biotherapeutics for Pediatric Patients" 2013 AAPS NBC Meeting (2013)
"Novel Applications of PBPK Models" PK/PD summit (2013)
"Overcoming PK/PD barriers to link drug levels with the biological effects in a tumor" 2013 Tumor Model Conference (2013)
"A platform PBPK model to characterize the plasma and tissue disposition of mAbs" The 2012 Rozman Symposium, The Delaware Valley DRUG METABOLISM DISCUSSION GROUP (2012)
"Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale Mechanistic PK/PD Model: A Case Study with SGN-35" 2012 World-Wide Webinars: Impact of Modeling and Simulation in Drug Development., ROSA‘s (2012)
"Preclinical-to-clinical translation of ADC efficacy using the multi-scaled mechanistic PK/PD model" 3rd Pharmacokinetics & Pharmacodynamics Conference, GTC (2012)
"Using Mechanistic Preclinical PK/PD Studies to Inform Dose, Dose Regimen Selection and Beyond: Can we make Preclinical Models more Predictive?." World ADC Summit (2012)
"Mechanistic Modeling for Rational Selection of Clinical Doses for Biologics" , AAPS (2011)
"Treating ovarian cancer using combination of anti-angiogenic therapy and intraperitoneal chemotherapy" , AAPS (2010)
"Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy" , University at Buffalo, Pharmaceutical Sciences (2009)
"A Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy" PGSRM (2009)
"Application of anti-angiogenic therapy to improve drug penetration in solid tumors, following regional chemotherapy" UB/Pfizer monoclonal antibody videoconference (2007)
"The role of dehydration and transepidermal water loss in skin barriers function" (2003)